Introduction {#s01}
============

In virtually all eukaryotic cells, lipid droplets (LDs) play central roles in lipid and energy metabolism and their deregulation is associated with metabolic disorders such as obesity, diabetes, and lipodystrophy ([@bib37]). At structural level, LDs are rather unique: a hydrophobic core composed of neutral lipids, mainly triglycerides and sterol esters, surrounded by a monolayer of phospholipids acting as surfactants and a specific set of proteins ([@bib21]; [@bib61]; [@bib51]). This structural organization of LDs favors the binding of proteins with hydrophobic α-helical hairpins or amphipathic helices (AHs), whereas it precludes the association of integral membrane proteins with luminal domains. Proteins with AHs are thought to be recruited to LDs directly from the cytosol, whereas the ones with hydrophobic hairpins are first targeted to the ER before concentrating at the LD monolayer ([@bib61]; [@bib51]). In both cases, the targeting appears to be highly regulated. This set of LD-specific proteins, mostly consisting of lipid-modifying enzymes and regulatory proteins, to a large extent determines many of the LD properties. The ER is also involved in the synthesis of most of the lipids both at the surface and in the hydrophobic core of LDs. Moreover, a large fraction of (in mammals) or all (in yeast) LDs are continuous with the ER ([@bib34]; [@bib67]). Therefore, how these biochemically and physically connected organelles achieve and maintain their identity is a major question in cell biology.

Depending on the cell type or metabolic state, LDs vary widely in number, size, and composition ([@bib70]). The molecular mechanisms controlling these aspects of LD biology are largely unknown, but changes in phospholipid biosynthesis were shown to influence LD morphology ([@bib27]; [@bib36]; [@bib19]). Phospholipid imbalances, particularly defects leading to a decrease in the levels of phosphatidylcholine (PC), induce the formation of abnormally large LDs (i.e., "supersized"). For example, mutations in *CHO2* or *OPI3*, components of the phosphatidylethanolamine *N*-methyltransferase pathway for PC biosynthesis, lead to supersized LDs in the yeast *Saccharomyces cerevisiae* ([@bib19]). In this case, the supersized LDs appear to form by coalescence of smaller ones as a consequence of both a decrease in levels of PC, which acts as a surfactant to prevent LDs coalescence ([@bib36]), together with increased amounts of phosphatidic acid (PA), which is thought to have fusogenic properties ([@bib10]; [@bib71]). Consistent with these data, activation of an alternative pathway for PC biosynthesis, the Kennedy pathway, restores the PA/PC ratio and LD morphology. Similarly, depletion of the Kennedy pathway rate-limiting enzyme CCT1 (CTP:phosphocholine cytidylyltransferase) in *Drosophila melanogaster* cells also induces the coalescence of small LDs into supersized LDs ([@bib27]; [@bib36]). Whether a general imbalance in phospholipid composition is the only or the major mechanism leading to the formation of supersized LDs is unclear.

Seipin is an evolutionarily conserved ER membrane protein that has been implicated in regulating LD morphology, but its function is not well understood. It was originally identified as being mutated in patients with Berardinelli-Seip congenital lipodystrophy ([@bib46]). These patients display almost complete absence of adipose tissue, ectopic fat accumulation, and altered glucose metabolism, a phenotype recapitulated in mice and flies upon targeted ablation of seipin ([@bib13]; [@bib62]; [@bib9]; [@bib52]).

At the cellular level, the major defect caused by seipin mutations is observed in LDs, which appear smaller and aggregated ([@bib59]; [@bib4]; [@bib18]). In *S. cerevisiae* lacking the seipin homolog Fld1, a fraction of cells displays similar LD defects ([@bib59]; [@bib17], [@bib19]; [@bib66]). In the rest of *fld1Δ* cells, LDs are still abnormal, but instead of small and aggregated, they appear in reduced number and supersized. Although resembling those observed in the *N*-methyltransferase pathway mutants *opi3Δ* or *cho2Δ*, supersized LDs in *fld1Δ* cells are not rescued by stimulation of the Kennedy pathway, indicating that they are caused by a different defect ([@bib19]; [@bib66]). Interestingly, the distinct morphologies of abnormal LDs in *fld1Δ* cells can be manipulated by inositol, a phospholipid precursor with a central role in glycerolipid metabolism ([@bib30]). At low inositol concentrations supersized LDs are seen in a large fraction of *fld1Δ* cells; in contrast, if inositol concentration is high the frequency of supersized LDs decreases with a concomitant increase in LD aggregates ([@bib19]; [@bib66]). This observation suggests that the LD defects in *FLD1* mutants might derive from abnormal phospholipid homeostasis. However, robust and consistent changes in global phospholipid composition have not been detected in seipin mutants, in yeast, or in any other cell type ([@bib59]; [@bib17], [@bib18],[@bib19]; [@bib66]).

In yeast, Fld1 binds to and is necessary for the stability of Ldb16, another ER membrane protein ([@bib66]). Fluorescence microscopy experiments suggest that the two proteins localize to the ER--LD contact sites ([@bib59]; [@bib17]; [@bib66]). Moreover, the LD phenotypes of *fld1Δ* and *ldb16Δ* are remarkably similar, further indicating they have a common unknown function in LD formation ([@bib66]).

Here we show that the Fld1/Ldb16 complex is required for the identity of LDs in *S. cerevisiae*. In the absence of this complex, incorporation of phospholipids into the monolayer of nascent LDs is entirely dependent on the ER phospholipid pools, leading to the generation of membrane defects and abnormal localization of LD and other lipid-binding proteins. In *fld1Δ* and *ldb16Δ* mutants, these defects are a consequence of abnormal ER--LD contact sites, as demonstrated by electron tomography. We propose that stabilization of ER--LD contact sites by the Fld1/Ldb16 complex establishes a diffusion barrier necessary for normal LD morphology and identity.

Results {#s02}
=======

Fld1/Ldb16 complex mutants are defective in uncoupling LD biogenesis from phospholipid synthesis {#s03}
------------------------------------------------------------------------------------------------

The changes in LD morphology induced by inositol supplementation are unique to *fld1Δ* and *ldb16Δ* mutants, and its presence does not induce LD aggregates in *wt* cells or in other mutants with LD defects ([@bib19]; [@bib66]). Inositol is a precursor of phosphatidylinositol, and, if supplemented to the yeast growth media, it strongly stimulates phosphatidylinositol synthesis ([@bib30]). This raises the possibility that LD morphology in *fld1Δ* and *ldb16Δ* cells is sensitive to changes in phospholipid synthesis ([@bib7]). To directly test this hypothesis, we stimulated phospholipid biosynthesis in an inositol-independent manner by overexpressing the CDP-diacylglycerol synthase *CDS1*, which converts PA into CDP-DAG, a key step in the synthesis of most phospholipids in yeast ([@bib56]). Overexpression of *CDS1* did not affect LD morphology in *wt* cells ([Fig. 1](#fig1){ref-type="fig"}). In contrast, increasing Cds1 levels in *fld1Δ* and *ldb16Δ* cells resulted in complete disappearance of supersized LDs and formation of LD aggregates. These were indistinguishable from the ones induced by inositol supplementation ([Fig. 1](#fig1){ref-type="fig"}), suggesting that the effect is caused by the stimulation of phospholipid synthesis. Thus, together with previous experiments ([@bib19]; [@bib66]; [@bib7]), these data indicate that the Fld1/Ldb16 complex uncouples LD growth from ER phospholipid pools.

![**Fld1/Ldb16 complex mutants are defective in uncoupling LD morphology from phospholipid synthesis.** Analysis of LD morphology in cells with the indicated genotype. Cells were grown in SC or SC supplemented with 75 µM inositol to early stationary phase. Yellow arrowheads indicate supersized LDs; white arrowheads indicate LD aggregates. LDs were stained with MDH. Bar, 5 µm.](JCB_201502070_Fig1){#fig1}

Abnormal LD composition in Fld1/Ldb16 complex mutants {#s04}
-----------------------------------------------------

As a first step in dissecting the mechanism by which Fld1/Ldb16 complex uncouples LD biogenesis from phospholipid biosynthesis, we purified LDs from cells grown in presence or absence of inositol and analyzed their composition. To assess the purity of the isolated organelles, the presence of several marker proteins in the different fractions was analyzed by Western blotting ([Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp1}). A specific enrichment of LD proteins with negligible amounts of ER proteins was detected in the LD fraction. Negative stain electron microscopy of isolated LDs also indicated minimal, if any, microsomal contamination (Fig. S1 B). These data confirmed the high quality of the LD preparations and also indicated that the buoyant properties of LDs from *wt*, *fld1Δ*, and *ldb16Δ* are not drastically different. Interestingly, the morphology of isolated LDs recapitulated well the in vivo situation. Whereas LDs isolated from *wt* cells were regular in size and highly circular in cross section, the ones from *ldb16Δ* cells were extremely irregular, both in size and circularity.

To characterize the LDs of *ldb16Δ* or *fld1Δ* cells, we first determined their lipid composition. The LDs isolated from *wt* and mutant cells grown in regular minimal medium (no inositol supplementation) showed a similar composition, both at the level of phospho- and neutral lipids ([Fig. 2 A](#fig2){ref-type="fig"}). Similarly, the composition LDs isolated from *wt* cells grown with or without inositol supplementation did not change. In contrast, LDs isolated from *ldb16Δ* or *fld1Δ* cells grown in inositol-supplemented medium, although maintaining similar neutral lipid content, were highly enriched in PC and phosphatidylethanolamine (PE), the major ER phospholipids ([Fig. 2 A](#fig2){ref-type="fig"}). The changes were specific to the LD fraction as the whole-cell lipid composition was indistinguishable between mutant and *wt* cells (Fig. S1 C). Given the high purity of the isolated LDs, this increase in phospholipids cannot be attributed to ER contamination of the LD fraction. Instead, these data are consistent with the increased surface to volume ratio of LDs in the aggregates observed in *fld1Δ* and *ldb16Δ* cells grown under conditions stimulating phospholipid synthesis.

![**Abnormal composition of LDs in Fld1/Ldb16 complex mutants.** (A) Lipid composition of LDs isolated from cells with the indicated genotype and grown in SC or SC supplemented with 75 µM of inositol (+INO). LDs from *wt* cells grown in SC media were used as reference. The result of at least three independent experiments is shown in the graph; whiskers represent the maximum and minimum values. (B) Localization of the LD-specific proteins Osw5, Pet10, Tgl1, and Yeh1 in *wt*, *ldb16Δ*, and *fld1Δ* cells grown in YPD until early stationary phase. All proteins were expressed from their endogenous locus as C-terminal GFP fusions. Yellow arrowheads indicate supersized LDs and white arrowheads indicate LD aggregates. LDs are stained with the neutral lipid dye MDH. Bar, 5 µm.](JCB_201502070_Fig2){#fig2}

Next we compared the LD proteome of *wt* and mutant cells using label-free quantitative mass spectrometry. Protein composition of LDs isolated from *fld1Δ* and *ldb16Δ* mutants were similar between them but very distinct from LDs of *wt* cells. Among the 30--40 high-confidence LD proteins ([@bib26]; [@bib14]), 27 were strongly reduced or completely absent from *ldb16Δ* and *fld1Δ* LDs ([Table S1](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp2}) suggesting a global defect in protein targeting in these mutants. To validate the proteomic data, many of these proteins were expressed from their endogenous locus as C-terminal GFP fusions and their localization evaluated by fluorescence microscopy. In agreement with the mass spectrometric data, all tested LD proteins were strongly reduced or completely absent from the LD surface in *ldb16Δ* or *fld1Δ* mutants ([Fig. 2 B](#fig2){ref-type="fig"} and not depicted). The changes did not appear to be caused by an overall decrease in protein levels, which for the tested proteins were comparable in *wt* and mutant cells (Fig. S1 A and not depicted). Importantly, the magnitude of the defect varied depending on the LD morphology. Although LD proteins were decreased but still visible in supersized LDs, they were undetectable in the aggregates ([Fig. 2 B](#fig2){ref-type="fig"}), suggesting that these morphologically distinct LDs have monolayers with different properties. Altogether, these data show that Ldb16 and Fld1 are required for the localization of LD-specific proteins.

Lipid-driven relocalization of Opi1 in Fld1/Ldb16 complex mutants {#s05}
-----------------------------------------------------------------

The proteomic analysis of LDs revealed a second major distinction between organelles isolated from *wt* and *ldb16Δ* or *fld1Δ* mutant cells. A group of peripheral membrane proteins that in *wt* cells do not associate with LDs was highly enriched in organelles isolated from *ldb16Δ* and *fld1Δ* mutants ([Table S2](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp3}). The most abundant of these proteins was Opi1, a transcriptional repressor whose activity is controlled by association with the membrane of the ER ([@bib42]). In the nucleus, Opi1 represses the activation of many genes, including phospholipid biosynthetic genes ([@bib30]). Under conditions of active phospholipid synthesis, Opi1 is bound to the ER membrane in an inactive state. The membrane association of Opi1 involves a bipartite signal: through its FFAT motif, Opi1 binds to the ER membrane protein Scs2; through a short lysine-rich segment (Q2), Opi1 is thought to bind to PA, a precursor for most cellular phospholipids as well as triglycerides ([@bib41], [@bib42]). To validate the mass spec data, we analyzed the localization of endogenous Opi1 C-terminally tagged with mCherry (Opi1-Cherry). In *wt* cells, Opi1-Cherry was uniformly distributed at the nuclear ER as expected ([Fig. 3 A](#fig3){ref-type="fig"}; [@bib41]). In cells lacking Ldb16 or Fld1, Opi1-Cherry still overlapped with the nuclear ER marker Hmg1-GFP; however, its distribution was uneven forming 1--3 *foci*/cell often in close proximity to abnormal aggregated or supersized LDs ([Fig. 3 A](#fig3){ref-type="fig"} and not depicted).

![**Lipid-driven relocalization of Opi1 in Fld1/Ldb16 complex mutants.** (A) Localization of Opi1 in *wt* and *ldb16Δ* cells grown in SC media to early stationary phase. Opi1 was expressed from the endogenous locus as C-terminal mCherry fusion (Opi1-Cherry). Nuclear envelope was labeled by endogenously expressed Hmg1-GFP. LDs were stained with the neutral lipid dye MDH. Yellow arrowheads indicate supersized LDs; white arrowhead indicates LD aggregates. Bar, 5 µm. (B) Localization of endogenously expressed Opi1-GFP in cells with the indicated genotype grown to early stationary phase in SC media. LDs were stained with the neutral lipid dye MDH. Bar, 5 µm. (C) Localization of GFP-Spo20^51--91^ expressed from a 2 µm plasmid in cells with the indicated genotype. LDs were stained with the neutral lipid dye MDH. Bar, 5 µm. (D) Percentage of cells with the indicated genotype displaying abnormal *foci* of GFP-Spo20^51--91^. Late logarithmic cells grown in SC media (−) or SC supplemented with 75 µM inositol (+) are shown. The mean of two independent experiments is graphed; error bars represent SD. For each genotype and condition, at least 100 cells/experiment were analyzed.](JCB_201502070_Fig3){#fig3}

Next, we investigated the determinants leading to Opi1 relocalization in *ldb16Δ* and *fld1Δ* cells. First, we tested the involvement of its membrane-bound partner Scs2. In *scs2Δ* cells, Opi1-GFP is mostly nuclear ([Fig. 3 B](#fig3){ref-type="fig"}), as previously shown ([@bib41]). In contrast, the localization of Opi1-GFP in *ldb16Δ scs2Δ* and *fld1Δ scs2Δ* double mutants is similar to that in single *ldb16Δ* and *fld1Δ* mutants ([Fig. 3 B](#fig3){ref-type="fig"}), suggesting that Scs2 is not involved in Opi1 *foci* formation. Moreover, although enriched in proximity of LD aggregates in *ldb16Δ* and *fld1Δ* mutants, Scs2 is normally distributed throughout the ER ([Fig. S2 A](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp4}). A similar distribution is observed for a GFP-fusion of the Opi1 FFAT domain (GFP-Opi1^FFAT^; Fig. S2 B). Thus, the aberrant distribution of Opi1 in *ldb16Δ* and *fld1Δ* mutants is independent of Scs2.

Next we tested whether the abnormal Opi1 distribution in the mutants relied on its lipid-binding activity, putatively to PA. A short Opi1 fragment rich in basic amino acids, Opi1^Q2^, was shown to bind to PA both in vivo and in vitro ([@bib42]). In *wt* cells, Opi1^Q2^ fused to GFP (GFP-Opi1^Q2^) localized mostly to the nucleus, as previously shown ([@bib42]). In *ldb16Δ* cells, besides the nuclear localization, GFP-Opi1^Q2^ formed *foci* resembling the Opi1-GFP although at a much lower frequency (Fig. S2 C). These results suggested that abnormal PA distribution could be the cause of Opi1 relocalization in seipin complex mutants. Therefore, we analyzed the distribution of GFP-Spo20^51--91^, a 40--amino acid fragment containing the AH of the SNARE Spo20 widely used as a PA biosensor ([@bib49]). In *wt* cells, GFP-Spo20^51--91^ localizes at the cell periphery ([Fig. 3 C](#fig3){ref-type="fig"}), as expected ([@bib49]). Besides the peripheral staining, *fld1Δ* and *ldb16Δ* mutant cells frequently displayed additional GFP-Spo20^51--91^ *foci*. These were often apposed to LDs and were reminiscent of those observed for Opi1-GFP. The GFP-Spo20^51--91^ spots were specific to *fld1Δ* and *ldb16Δ* cells and were not present in other mutants displaying supersized LDs, such as *opi3Δ* ([Fig. 3 C](#fig3){ref-type="fig"}). Curiously, in inositol-supplemented media, GFP-Spo20^51--91^ *foci* were detected at higher frequency ([Fig. 3 D](#fig3){ref-type="fig"}). Altogether, these data indicate that aberrant Opi1 distribution is driven by its lipid-binding domain. However, it is unlikely that abnormal PA accumulation is the cause of the defect as the relocalization of both Opi1-GFP and GFP-Spo20^51--91^ increases in presence of inositol, a condition that favors PA consumption (Fig. S2 D; [@bib42]).

Relocalization of amphipathic helix-containing proteins in seipin complex mutants {#s06}
---------------------------------------------------------------------------------

The other peripheral membrane proteins copurifying ectopically with *ldb16Δ* and *fld1Δ* LDs were very diverse in function and normal subcellular localization. However, they all contain or are predicted to contain an AH, a common motif involved in membrane association ([Table 1](#tbl1){ref-type="table"}; [@bib23]). These AH-containing proteins were expressed from their endogenous *loci* as C-terminal GFP fusions, and their distribution was analyzed by fluorescence microscopy ([Fig. S3 A](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp5}). When compared with *wt* cells, in *ldb16Δ* and *fld1Δ* mutants all the tested proteins were dramatically relocalized appearing as one to three foci/cell overlapping or proximal to LDs (Fig. S3 A and not depicted). These results confirmed the proteomic analysis of isolated LDs. Next, we asked whether the change in localization of those proteins required their AHs. In all tested cases, deletion of the AH abolished or dramatically decreased the relocalization of the proteins in *ldb16Δ* and *fld1Δ* mutants ([Fig. 4 A](#fig4){ref-type="fig"}). The drop in ectopic localization was observed irrespective of the inositol concentration ([Fig. 4 A](#fig4){ref-type="fig"}), which influences the morphology of LDs in the mutants, and was not caused by changes in the steady-state levels of proteins (Fig. S3 B). Finally, endogenous expression of the sole AH motif fused to GFP was sufficient for LD relocalization in *ldb16Δ* and *fld1Δ* cells ([Fig. 4 B](#fig4){ref-type="fig"}). Altogether, these results indicate that the relocalization of several proteins in *ldb16Δ* and *fld1Δ* cells is mediated by their AHs.

###### AH-containing proteins ectopically localized to LDs in *ldb16Δ* and *fld1Δ* cells

  **Protein**   **Localization**           **Function**                               **Type of AH**                   **Reference**
  ------------- -------------------------- ------------------------------------------ -------------------------------- ---------------
  **Pct1**      Nuclear envelope/nucleus   Cholinephosphate cytidylyltransferase      "Canonical"                      [@bib12]
  **Kes1**      Cytoplasm/Golgi            Oxysterol-binding protein                  ALPS                             [@bib16]
  **Vps13**     Cytoplasm/endosomes (?)    Unknown                                    ALPS                             [@bib16]
  **Gvp36**     Cytoplasm/Golgi vesicles   Unknown (BAR domain--containing protein)   AH (ALPS type) in N-BAR domain   [@bib23]

![**Relocalization of amphipathic helix-containing proteins in seipin complex mutants.** (A) Localization of GFP-tagged Kes1, Pct1, Gvp36, and the corresponding counterparts lacking the AH Kes1^Δ2--29^, Pct1^Δ261--282^, and Gvp36^Δ2--35^ in cells with the indicated genotype. The GFP fusion proteins were expressed from a centromeric plasmid. Cells in early stationary phase grown in SC media (I−) or SC supplemented with 75 µM inositol (I+) were imaged. LDs were stained with the neutral lipid dye MDH. Bar, 5 µm. On the right the percentage of cells with the indicated genotype displaying abnormal *foci* of GFP-tagged proteins. The mean of three independent experiments is displayed; error bars represent SD. At least 100 cells/experiment were analyzed per genotype. (B) Localization of Kes1(1--38)-GFP and Gvp36(1--50)-GFP in cells with the indicated genotype grown in SC supplemented with inositol. Kes1(1--38)-GFP and Gvp36(1--50)-GFP were expressed from the endogenous *loci* and encode for AH of Kes1 and Gvp36, respectively. LDs were stained with the neutral lipid dye MDH. Bar, 5 µm.](JCB_201502070_Fig4){#fig4}

Seipin complex mutants display phospholipid-packing defects {#s07}
-----------------------------------------------------------

AHs do not act as simple membrane anchors but can play an active role in deforming lipid membranes or sensing membrane packing defects, thereby controlling membrane-related processes ([@bib15]; [@bib6]). Moreover, the chemical properties of AHs can vary significantly and determine the binding preferences to target membranes. Intriguingly, Kes1 and Pct1, two of the ectopically localized proteins in the mutant cells, contain AHs with very distinct chemical properties. The AH of Pct1, the yeast CTP:phosphocholine cytidylyltransferase, has a highly charged polar face ([Fig. 5 A](#fig5){ref-type="fig"}). In contrast, the AH of the lipid transfer protein Kes1 has a polar face enriched in serine/threonines and poor in charged residues ([Fig. 5 A](#fig5){ref-type="fig"}). This latter type of AH is also known as ALPS (amphipathic lipid packing sensor) domain and was shown to recognize lipid packing defects arising either from membrane curvature or accumulation of conical lipids in flat membranes ([@bib16]; [@bib64]; [@bib65]; [@bib6]).

![**Phospholipid packing defects in Fld1/Ldb16 complex mutants.** (A) Helical-wheel representation of the AH of Pct1 and Kes1 as predicted and drawn by Heliquest ([@bib23]). Both AHs display a well-defined face enriched in hydrophobic residues (yellow). In contrast, the polar faces are very distinct: in Pct1, it is enriched in charged residues (blue and red), whereas in Kes1, the abundance of noncharged serine and threonine residues (purple) dominates. (B) Localization of Pct1 and Kes1 in *wt* and *ldb16Δ* cells grown in SC media to early stationary phase. Proteins were expressed from their endogenous locus as C-terminal mCherry fusions. Nuclear envelope is labeled by endogenously expressed Hmg1-GFP. LDs are stained with the neutral lipid dye MDH. Yellow arrowheads indicate supersized LDs; white arrowheads indicate LD aggregates. Bar, 5 µm. (C) Electron micrographs showing immunolocalization of endogenously expressed Pct1-GFP in *ldb16Δ* cells. Logarithmic cultures in YPD were processed for immuno-EM as described in the Materials and methods section. Arrowheads point to 12 nm immunogold particles specifically labeling Pct1-GFP in association with nuclear LDs. NE, nuclear envelope; N, nucleus. Magnified insets are shown on the right of each micrograph. Bars, 200 nm. (D) Localization of endogenously expressed Kes1-GFP and Pct1-mCherry in *wt*, *ldb16Δ*, and *fld1Δ* cells. Late logarithmic cultures in SC media or SC supplemented with 75 µM inositol (SC + INO) were imaged. LDs are stained with the neutral lipid dye MDH. Bar, 5 µm.](JCB_201502070_Fig5){#fig5}

Given the distinct properties of their AHs, the distribution of Kes1 and Pct1 was analyzed in detail. In *wt* cells, both Pct1-Cherry and Kes1-Cherry had a diffuse distribution as expected ([@bib45]; [Fig. 5 B](#fig5){ref-type="fig"}). In *ldb16Δ* and *fld1Δ* mutants, Pct1-Cherry formed *foci* proximal, but not completely overlapping with abnormal LDs, both supersized and aggregated ([Fig. 5 B](#fig5){ref-type="fig"}). Using immuno-EM, we confirmed that in mutant cells, Pct1 concentrated at the surface of a subset of LDs ([Fig. 5 C](#fig5){ref-type="fig"} and [Table S3](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp6}, top). Interestingly, Pct1 was detected primarily in LDs present in the nucleus, which have been previously seen in *fld1Δ* mutants ([@bib7]). Consistent with the different chemistry of its AH, the foci formed by Kes1-Cherry were distinct from the ones of Pct1. Kes1-Cherry foci perfectly overlapped with the LD aggregates ([Fig. 5 B](#fig5){ref-type="fig"}) The association of Kes1 with LD aggregates was confirmed by immuno-EM (Fig. S3 C and Table S3). Remarkably, by fluorescence microscopy, Kes1 was never seen at supersized LDs, indicating that the monolayers of aggregated and supersized LDs have different properties.

In cells coexpressing Pct1 and Kes1 as Cherry and GFP fusions, respectively, we confirmed that, in *ldb16Δ* and *fld1Δ* mutants, these proteins relocalize to proximal but distinct regions, likely as a consequence of the different chemical properties of their AHs ([Fig. 5 D](#fig5){ref-type="fig"}). Accordingly, Vps13 and Gvp36, that like Kes1 contain AHs of the ALPS type also localize to LD aggregates (Fig. S3 D). In sum, these data indicate that in *ldb16Δ* and *fld1Δ* mutants, LDs display phospholipid packing defects that are recognized by AHs with different specificities.

Membrane defects in seipin complex mutants are caused by LD assembly {#s08}
--------------------------------------------------------------------

Mutations in *FLD1* and *LDB16* might have a general effect on membrane properties causing the observed defects in LD morphology and protein localization. Alternatively, the membrane defects might derive specifically from abnormal LD assembly in these mutants. To discriminate between these possibilities, we analyzed the distribution of Pct1, GFP-Spo20^51--91^, and Kes1 in cells lacking LDs, as is the case of the quadruple mutant *are1Δ are2Δ dga1Δ lro1Δ* (*Qmut*) unable to synthesize neutral lipids ([@bib55]; [@bib58]). The distribution of these proteins was indistinguishable between *wt* and *Qmut* cells ([Fig. 6 A](#fig6){ref-type="fig"} and [Fig. S4, A and B](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp7}). Importantly, the abnormal localization of Pct1, GFP-Spo20^51--91^ and Kes1 induced by *ldb16Δ* and *fld1Δ* mutations was completely reverted in the absence of LDs, such as the quintuple mutants *are1Δ are2Δ dga1Δ lro1Δ ldb16Δ* and *are1Δ are2Δ dga1Δ lro1Δ fld1Δ* ([Fig. 6 A](#fig6){ref-type="fig"} and Fig. S4, A and B).

![**LD assembly causes phospholipid-packing defects in seipin complex mutants.** (A) Localization of GFP-Pct1 and GFP-Spo20^51--91^ in cells with (*wt* and *ldb16Δ*) and without LDs (*are1Δ are2Δ dga1Δ lro1Δ* and *are1Δ are2Δ dga1Δ lro1Δ ldb16Δ*). Cells were grown in SC media up to early stationary phase. LDs were stained with the neutral lipid dye MDH. Bar, 5 µm. (B) Localization of GFP-Pct1 and GFP-Kes1 at the indicated time points upon induction of LD formation. LDs were induced by expression of the triglyceride-synthesizing enzyme Dga1 from a regulatable promoter in *are1Δ are2Δ lro1Δ* (LD^Switch^) or *are1Δ are2Δ lro1Δ ldb16Δ* (*ldb16Δ* LD^Switch^) cells. LDs were stained with the neutral lipid dye MDH. Bar, 5 µm. (C) Kinetics of LD formation and appearance of GFP-Pct1 (left) or GFP-Kes1 (right) *foci* in *ldb16Δ* LD^Switch^ cells. Cells were grown in minimal media supplemented with 75 µM inositol until early stationary phase. The percentages of *ldb16Δ* LD^Switch^ cells displaying LDs (black line) or foci of the indicated GFP-tagged protein (gray line). Expression of Dga1 was induced at time zero. The mean of two independent experiments is displayed; error bars represent SD. At least 100 cells/time point were analyzed in each experiment.](JCB_201502070_Fig6){#fig6}

Next we followed LD assembly in cells lacking *are1Δ are2Δ lro1Δ* in which *DGA1* is under the control of an inducible promoter (LD^Switch^) either in presence or absence of *LDB16* and *FLD1*. Time-course experiments showed that relocalization of Pct1 and Kes1 follows the appearance of LDs ([Fig. 6, B and C](#fig6){ref-type="fig"}). Moreover, the abnormal LD morphology in seipin complex mutants was not reverted by additional deletion of Pct1 or any of the other proteins localizing ectopically to LDs (Fig. S4 C and not depicted). These data show that the membrane defects are a consequence of abnormal LD formation in *ldb16Δ* and *fld1Δ* mutants. Moreover, they suggest that the seipin complex organizes ER membrane domains required specifically during LD assembly.

Destabilized ER--LD contact sites in seipin complex mutants {#s09}
-----------------------------------------------------------

To gain further insight into the membrane defects induced during LD biogenesis in *ldb16Δ* and *fld1Δ* mutants, we performed dual-axis electron tomography of high-pressure frozen and freeze-substituted cells. This approach allowed us to resolve at high definition LDs, adjacent ER regions, and ER--LD contact sites. In *wt* cells, LDs had a smooth contour, were invariably in contact with the ER, and regions previously described as ER--LD bridges were seen ([Fig. 7 A](#fig7){ref-type="fig"} and [Videos 1](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp8} and [2](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp9}). The structure of the ER at the contact sites was highly regular, with the luminal space showing a uniform width throughout. This was in striking contrast with the LDs observed in *ldb16Δ* mutants, irrespective of whether they were supersized or aggregated. In both cases, the contour of LDs appeared frequently wrinkled and irregular and ER--LD contact sites were noticeably abnormal. In the case of supersized LDs, the ER membrane contacting the LD protruded in a nipple-like structure toward the LD resulting in an abnormal expansion of ER luminal width ([Fig. 7 B](#fig7){ref-type="fig"} and [Videos 3](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp10} and [4](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp11}). The luminal expansion was circumscribed to the contact site with supersized LDs, and other ER regions appeared largely normal. In the case of aggregated LDs, observed in cells with active phospholipid synthesis, contact sites had a peculiar appearance. Overall, the contact site was enlarged with prominent ER protrusions molded around the LDs in the aggregate ([Fig. 7 C](#fig7){ref-type="fig"}). If in most cases ER and LDs were apposed but clearly identified as separate structures, regions with appearance of ER--LD bridges were also detected ([Fig. 7 C](#fig7){ref-type="fig"} and [Videos 5](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp12}, [6](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp13}, and [7](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp14}). Expansion of ER luminal width was frequently observed and in most cases was not restricted to the ER contact sites with the aggregated LDs, and bloated ER cisternae could be seen away from the aggregates ([Fig. 7 C](#fig7){ref-type="fig"} and Video 7). The expanded ER lumen was electrotranslucent, with an appearance similar to the neutral lipid core of LDs. Abnormal ER--LD contact sites in this mutant suggest that Ldb16 functions at interface of the two organelles, where it appears to localize with Fld1 based on fluorescent microscopy experiments ([@bib59]; [@bib17]; [@bib66]). Indeed, using immuno-EM, we detected that functional Ldb16-GFP expressed from its endogenous locus localizes specifically at the ER--LD contact sites ([Fig. 7 D](#fig7){ref-type="fig"} and [Table S4](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp15}). Altogether, these data indicate that Fld1/Ldb16 complex is required for the stability of ER--LD contact sites.

![**Destabilized ER--LD contact sites in Seipin complex mutants.** (A) 2D tomograms derived from 250-nm-thick sections of *wt* cells. Magnified insets on the right of each tomogram show ER--LD contact sites (arrowhead). Bars, 200 nm. (B) 2D tomograms derived from a 250-nm-thick sections of *ldb16Δ* cells. Magnified insets on the right of each tomogram show the contact sites between ER and supersized LDs (arrowhead). Bars, 200 nm. (C) 2D tomograms derived from a 250-nm-thick sections of *ldb16Δ* cells. Arrows indicate ER regions with enlarged luminal width. Bars, 200 nm. (D) Electron micrographs showing immunolocalization of endogenously expressed Ldb16-GFP in *wt* cells. Arrows point to 12-nm immunogold particles labeling specifically Ldb16-GFP. Bars, 100 nm. C, cytoplasm; N, nucleus.](JCB_201502070_Fig7){#fig7}

Discussion {#s10}
==========

Here we characterized the function of the yeast seipin complex in LD biogenesis. LD assembly in the absence of Fld1/Ldb16 led to membrane defects in LDs and proximal ER regions and to abnormal LDs, which were either supersized or small and aggregated. Moreover, we showed that the determinant between these contrasting LD morphologies was the availability of ER phospholipid pools, indicating that Fld1/Ldb16 is important during LD biogenesis to couple the amounts of monolayer and core lipids. Structural analysis indicated that the defects were the result of abnormal ER/LD contact sites in *ldb16Δ* and *fld1Δ* mutants. We propose that stabilization of ER--LD contact sites by the seipin complex establishes a diffusion barrier controlling LD assembly and membrane identity ([Fig. 8](#fig8){ref-type="fig"}).

![**Fld1/Ldb16 complex stabilizes and establishes a diffusion barrier at the ER--LD contact sites.** (A) The scheme illustrates a contact site between the ER and a LD. Although connected with the ER membrane, the LD monolayer has different properties such as a higher surface tension (in orange). The presence of the Fld1/Ldb16 complex at the contact sites prevents the equilibration of the two membrane systems. (B) In the absence of this complex, phospholipids freely diffuse between the two organelles. Under low-synthesis conditions, phospholipids can become limiting and LDs coalesce into a supersized one. The mild surface tension (faint orange) in these LDs still allows the targeting of LD proteins, albeit at lower efficiency (left). Under high-phospholipid-synthesis conditions, ER membrane and LDs equilibrate. The low surface tension of these LDs prevents their coalescence and the recruitment of LD proteins. Instead, these aggregates display phospholipid packing defects (green), which recruit ALPS-motif--containing proteins (right). Both low and high phospholipid synthesis leads to phospholipid defects in membranes adjacent to LDs, which are recognized by proteins containing canonical AHs (brown).](JCB_201502070_Fig8){#fig8}

Changes in phospholipid composition, in particular defects in the PC synthesis, lead to abnormal LD morphology ([@bib27]; [@bib36]; [@bib19]). This is unlikely the reason of LD abnormalities in *fld1Δ* and *ldb16Δ* mutants, as we and others could not detect significant changes in their lipidome ([@bib17], [@bib19]; [@bib66]). In contrast, we showed that the morphology of LDs in these mutants is determined by phospholipid synthesis, as previously suggested ([@bib7]). In agreement with our results, unperturbed *fld1Δ* and *ldb16Δ* cells display mainly LD aggregates during logarithmic growth, a condition favoring phospholipid synthesis, whereas the supersized LD phenotype dominates as cells approach stationary phase, when phospholipid synthesis is reduced ([@bib66]; unpublished data).

The effect of phospholipid availability on LD morphology correlates well with the content of phospholipids in LDs. Under conditions that stimulate phospholipid synthesis, LDs isolated from mutant cells had a dramatic increase in phospholipids. This was not because of ER contamination of the isolated LDs and was consistent with the increased surface-to-volume ratio of LDs in aggregates. However, according to our EM data, the highly wrinkled contour of LDs in the mutant cells also contributes to the increased amounts of phospholipids. Moreover, in the aggregates, structures resembling ER--LD bridges likely facilitate the free diffusion of phospholipids between ER and LDs. The combined effect of the changes resulted in a higher content of the major ER phospholipids in LD aggregates. Under low-synthesis conditions, phospholipids become limiting and supersized LDs, with lower surface-volume ratio, formed. These still displayed an irregular contour. Thus, this dependence of LD morphology on ER phospholipid pools, not seen for any other mutant with abnormal LDs, results from destabilized ER--LD contact sites in *fld1Δ* and *ldb16Δ* mutants.

AHs adsorb to membranes exposing phospholipid packing defects ([@bib15]; [@bib6]). The recruitment of AH-containing proteins to LDs and ER proximal regions indicates the presence of membrane packing defects in *fld1Δ* and *ldb16Δ* mutants. Importantly, these are a direct consequence of LD assembly, as in time-course experiments, their appearance follows LD biogenesis. Interestingly, proteins containing AHs of different chemistry are recruited to distinct subpopulations of LDs. The AH of Kes1, a prototypical ALPS motif, binds to membranes with phospholipid packing defects generated by high curvature or accumulation of conical phospholipids (such as PE) in a flat membrane ([@bib16]; [@bib64]; [@bib65]). In vitro studies demonstrated that Kes1 ALPS binds to small liposomes (in the range of 30--40 nm in diameter), but not to bigger ones ([@bib16]). Crude measurements suggest that the diameter of individual LDs in the aggregates are bigger (\>80 nm). Therefore, it is possible that the ectopic recruitment of ALPS-containing proteins to LD aggregates in *fld1Δ* and *ldb16Δ* LDs is caused by the combined effect of curvature and increased levels of PE, a conic-shaped lipid, present in these structures. On the other hand, the AHs of Pct1 and Spo20 appear canonical and likely associate with membranes by a combination of both hydrophobic and electrostatic interactions ([@bib15]). Although the Pct1 AH has not been extensively characterized biochemically, the AH of Spo20 (Spo20^51--91^) was shown to bind to PA-rich membranes in vivo ([@bib49]; [@bib33]); however, recent in vitro studies suggest a general preference for anionic phospholipids and not necessarily for PA ([@bib33]). A preference for PA, preferably with shorter acyl chains, was also observed for the Q2 region of Opi1 ([@bib42]; [@bib31]). We detected only a small increase in whole-cell levels of PA and no enrichment in LD lipid fractions; therefore, Spo20^51--91^ and Opi1^Q2^ likely recognize some other feature at the nuclear envelope of *fld1Δ* and *ldb16Δ* mutants. The fact that conditions stimulating PA consumption, such as inositol supplementation or Cds1 overexpression, augment the relocalization of Spo20^51--91^ and Opi1 to *foci* at the nuclear envelope further argue against a PA-driven process, as previously proposed ([@bib19]; [@bib69]). In sum, we favor that unstable ER--LD contact sites in *fld1Δ* and *ldb16Δ* mutants, allowing uncontrolled phospholipid flow between the ER bilayer and LD monolayer, are prone to generate the packing defects recognized by AH-containing proteins. The spatial segregation of the different AHs possibly reflects differences in membrane curvature or surface tension.

The ectopic recruitment of AH-containing proteins to LDs observed in *fld1Δ* and *ldb16Δ* mutants can have several consequences. On one hand, it can deplete proteins from their site of function, potentially leading to a "loss of function" phenotype. This appears to be the case of Opi1, a negative regulator of Ino2/Ino4 required for transcription of most phospholipid biosynthetic genes ([@bib30]). In fact, several Ino2/Ino4 targets, such as *INO1* or *OPI3*, are upregulated in *fld1Δ* and *ldb16Δ* mutants ([@bib29]; [@bib19]; [@bib66]; unpublished data). However, upregulation of Ino2/Ino4 target genes is not the main cause of *fld1Δ* and *ldb16Δ* phenotype, as LDs are mostly normal in *opi1Δ* cells. On the other hand, ectopic concentration of AH-containing proteins at LDs can lead to local "gain of function" of these proteins. The phenotype of *fld1Δ* and *ldb16Δ* mutations was not modified by deleting individually Pct1, Kes1, Gvp36, or Vps13, suggesting that the ectopic recruitment of each one of these proteins per se is not responsible for the LD defects. This was further supported by time-course experiments showing that protein recruitment followed the formation of abnormal LDs in *fld1Δ* and *ldb16Δ* cells.

A major consequence of the loss of Fld1/Ldb16 is the global reduction of LD-specific proteins at the monolayer of these organelles. Many LD proteins are originally targeted to the ER before concentrating in the LD monolayer ([@bib70]; [@bib61]). It is possible that the crowding of the LD monolayer because of ectopic localization of AH-containing proteins precludes proper targeting of LD proteins. However, under conditions of overexpression, the LD-specific protein Dga1 was shown to localize normally in *fld1Δ* cells ([@bib34]), suggesting that the targeting of this protein is not defective. An alternative appealing possibility is that LD-specific proteins are able to target but are not retained/concentrated at the LD monolayer as a consequence of changes in surface tension owing to the free diffusion of phospholipids from the ER into LDs in *FLD1* and *LDB16* mutants. The wrinkled contour of LDs in these mutants indeed suggests changes in properties of the monolayer. Moreover, it is also consistent with the stronger protein targeting defect to LD aggregates, which have a higher content of phospholipids. In LDs that are not connected to the ER, the regulation of monolayer surface tension is essential in recruiting soluble proteins from the cytoplasm ([@bib36]; [@bib60]), in facilitating ER--LD reattachments ([@bib68]), and consequently in generating LD identity. It is possible that regulation of LD monolayer surface tension also plays a central role in concentrating proteins in LDs that remain connected to the ER. By stabilizing ER--LD contact sites, the Fld1/Ldb16 complex is well positioned to serve that function.

In contrast with most organelle contact sites, in which the membranes of two organelles are closely apposed ([@bib53]), at ER--LD contact sites the membranes of the two organelles merge, as the LD monolayer is continuous with the outer leaflet of the ER bilayer. Although the phospholipid classes in the two organelles are similar, the biophysical properties and protein composition of ER bilayer and LD monolayer are very distinct. We postulate that stabilization of these unique contact sites by Fld1/Ldb16 establishes a diffusion barrier necessary to regulate LD surface tension and identity. Potentially, such a barrier can also facilitate the concentration of neutral lipids and their packaging into nascent LDs. Future studies should test these hypotheses directly. Both Fld1 and Ldb16 form oligomers, which in the case of Fld1 appear to have a toroid shape ([@bib3]; [@bib66]). Whether and how these oligomerization events are controlled at ER--LD contact sites should also be addressed in follow-up work.

Materials and methods {#s11}
=====================

Reagents {#s12}
--------

The LD dyes Bodipy^493/503^ (Invitrogen) and monodansyl pentane (MDH; Abgent) were used at 1 µg/ml and 0.1 mM, respectively. Anti-HA (rat 3F10 monoclonal) antibody was purchased from Roche, anti-PGK1 (mouse) from Life Technologies, anti-GFP (rabbit) from Santa Cruz Biotechnology, Inc., and anti-RFP (mouse) from Abcam. Polyclonal anti-Usa1 antibody was raised against a C-terminal peptide of Usa1 and was previously described ([@bib8]). Recombinant protein fragments were used to raise polyclonal antibodies anti-Dga1 (amino acids 123--272) and anti-Pet10 (amino acids 148--283). All the antibodies were raised in rabbits, and sera anti-Dga1 and anti-Pet10 were affinity purified.

Yeast strains {#s13}
-------------

Protein tagging, promoter replacements, and individual gene deletions were performed by standard PCR-based homologous recombination ([@bib43]; [@bib35]). Strains with multiple gene deletions were made either by PCR-based homologous recombination or by crossing haploid cells of opposite mating types, followed by sporulation and tetrad dissection using standard protocols ([@bib28]). The strains used are isogenic either to BY4741 (*Mata ura3Δ0 his3Δ1 leu2Δ0 met15Δ0*) or to BY4742 (*Matα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0*) unless otherwise specified and are listed in [Table S5](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp16}.

Plasmids and primers {#s14}
--------------------

The *KES1* ORF (including 3′ UTR) was amplified by PCR from genomic DNA using primers 1688 and 1689. The obtained PCR fragment was digested using XhoI and BamHI and ligated to FLAG-GFP from pPC874 plasmid originating pPC1131. pPC1224, an equivalent plasmid encoding for Flag-GFP-Kes1^Δ2--29^ lacking Kes1 amphipathic helix was obtained by PCR mutagenesis using primer 1731. The PCT1 ORF (including 3′UTR) was amplified by PCR from genomic DNA using primers 1690 and 1691. The obtained PCR fragment was digested using XhoI and BamHI and ligated to FLAG-GFP from pPC874 plasmid originating pPC1130. pPC1226, an equivalent plasmid encoding for Flag-GFP-Pct1^Δ261--282^ lacking Pct1 amphipathic helix, was obtained by PCR mutagenesis using primer 1733. The *GVP36* ORF (including 3′UTR) was amplified by PCR from genomic DNA using primers 1686 and 1687. The obtained PCR fragment was digested using XhoI and BamHI and ligated to FLAG-GFP from pPC874 plasmid originating pPC1129. To generate pPC1184, encoding Gvp36-GFP, a PCR fragment encoding genomic Gvp36-GFP was amplified using genomic DNA from yPC5554 as template and primers 1817 and 185, digested with XhoI--XbaI cloned in pRS416. The predicted amphipatic helix (amino acids 2--35) was deleted by mutagenesis on this plasmid using primer 1818 to obtain the plasmid pPC1183. The DNA fragment encoding for ADH1p-GAL4-ER-VP16 was isolated by EcoRI (blunted using Klenow) and NotI digestion from the plasmid described in [@bib44], blunted using Klenow and ligated into SmaI--NotI-digested pRS415 giving rise to pPC924. The Q2 fragment from Opi1 containing residues 103--189 from Opi1 was amplified from genomic DNA using primers 1339 and 1340, digested with XhoI--HindIII, and cloned into the backbone of pPC670 in frame with FLAG-GFP originating pPC974. Plasmids and primers used in this study are listed in [Tables S6](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp17} and [S7](http://www.jcb.org/cgi/content/full/jcb.201502070/DC1){#supp18}, respectively.

Growth conditions {#s15}
-----------------

Strains were grown at 30°C in synthetic complete (SC; 0.17% yeast nitrogen base, 5 g/l ammonium sulfate, 2% glucose, and amino acids) or YPD liquid media (1% yeast extract, 2% peptone, and 2% glucose). For analysis of protein localization and LD morphology both late logarithmic phase (OD~600~ 2--3) and early stationary phase (OD~600~ 4--6) cultures were used. For phospholipids precursor treatment (I+), SC medium was supplemented with 75 µM inositol ([@bib22]).

LD induction system {#s16}
-------------------

For LD induction time courses, strains *GAL1-DGA1 are1Δ are2Δ lro1Δ* and *GAL1-DGA1 are1Δ are2Δ lro1Δ ldb16Δ*, bearing a plasmid encoding for the chimeric Gal4-VP16 transcription factor fused to the hormone-binding domain of the human estrogen receptor, were used ([@bib44]). This chimeric GAL4-ERE-VP16 protein provides galactose-independent activation of transcription of genes driven by *GAL* promoters (*DGA1* in this study) in response to β-estradiol. Cells were precultured in SC media lacking the appropriate amino acids until early stationary phase, diluted to OD 0.15 in 10 ml fresh media in 25-ml flasks at 30°C, and stimulated by addition of 100 nM β-estradiol. Time point 0 was imaged before induction with β-estradiol, and samples were acquired at the indicated time points, stained with MDH, and immediately imaged by live-cell fluorescence microscopy.

Fluorescence microscopy {#s17}
-----------------------

Fluorescence microcopy was performed at RT in a wide-field AF6000LX microscope (Leica) with an Andor iXon EMCCD camera and controlled by LAS AF software (Leica) or in a Cell Observer HS (Carl Zeiss) with a Hamamatsu CMOS camera ORCA-Flash4.0 controlled by 3i Slidebook6.0 software. A 100× 1.40 oil immersion objective was used. GFP and Bodipy^493/503^, mCHERRY, and MDH signals were detected using GFP filter, RFP filter cube, and DAPI filters, respectively, with standard settings.

LD isolation {#s18}
------------

LD purification was performed as previously described ([@bib40]; [@bib11]) with minor modifications. In brief, cells were grown in 500 ml YPD until stationary phase. Approximately 3,000 ODs of cells were centrifuged at 3,000*g* for 5 min (J J26-XP centrifuge, JLA8100 rotor), washed in milliQ water, preincubated in 0.1 M Tris-HCl, pH 9.5, and 10 mM DTT for 10 min at 30°C, washed, and resuspended in 50 ml spheroplasting buffer (1.2 M sorbitol and 50 mM Tris, pH 7.4). For spheroplast preparation, Zymolyase 20T (Seikagaku Biobusiness) was added (10 µg/OD~600~ unit cells) followed by incubation in a water bath at 30°C until a 10-fold drop in OD~600~ was observed (45--60 min). Spheroplasts were recovered by centrifugation (1,000 *g*, 4°C), washed with spheroplasting buffer, and resuspended in breaking buffer (BB; 10 mM MES, Tris, pH 6.9, 12% \[wt/wt\] Ficoll400, and 0.2 mM EDTA) at a final concentration of 0.3 g cells (wet weight)/ml. PMSF (1 mM) and Complete (Roche) were added before homogenization (loose-fitting pestle, 40 strokes) in a Dounce homogenizer on ice. The homogenate was centrifuged (5,000 *g*, 5 min) in J26-XP using rotor JS13.1. The resulting supernatant was transferred into 38ml Ultra-Clear centrifuge tubes (Beckman Coulter) and adjusted to 19 ml (cell lysate fraction), overlaid with an equal volume of BB and centrifuged (45 min, 30,000 rpm) in an optima L-100K centrifuge (Beckman Coulter) with an SW-32 swinging bucket rotor. The floating layer was collected from the top of the gradient and the LDs were further purified. The pellet was collected, resuspended in PBS, pH 7.4, with the help of a Dounce homogenizer, and fully dissolved with SDS--sample buffer (membranes fraction). For further purification of the LD fraction, the floating layer was gently resuspended in BB (five strokes in a Dounce homogenizer with loose-fitting pestle), adjusted to 19 ml with BB, transferred to a 38-ml Ultra-Clear tube, and overlaid with 19 ml of 10-mM MES-Tris, pH 6.9, 8% (wt/wt) Ficoll400, and 0.2 mM EDTA. Centrifugation was repeated as before (45 min, 30,000 rpm). The floating layer was collected and resuspended in 19 ml of 10-mM MES-Tris, pH 6.9, 0.6 M sorbitol, 8% (wt/wt) Ficoll400, and 0.2 mM EDTA, transferred to 38-ml Ultra-Clear tubes, overlaid with 19 ml of 10-mM MES-Tris, pH 6.9, 0.25 M sorbitol, and 0.2 mM EDTA, and centrifuged once more (30 min, 30,000 rpm). The recovered high-purity top LDs fraction was snap frozen, stored at −80°C, and used subsequently for proteomics and lipid analysis.

Immuno-EM {#s19}
---------

Yeast cells grown in YPD to OD~600~ ∼1 were fixed with 0.2% glutaraldehyde and 2% formaldehyde in 0.1 PHEM buffer (20 mM Pipes, 50 mM Hepes, pH 6.9, 20 mM EGTA, and 4 mM MgCl~2~) for 20 min at RT and overnight in the cold room with rolling. Cells were then processed for cryosectioning following the Tokuyasu method as described previously ([@bib25]). In brief, fixed cells were treated with 1% periodic acid in 0.1M PHEM for 60 min at room temperature, washed with 0.1 M PHEM, and embedded in 12% gelatin in the same buffer for 10 min at 37°C. Gelatin was allowed to solidify on ice for at least 60 min, and then cells were infiltrated in 2.3 M sucrose overnight at 4°C before processing into 1-mm^3^ cubes and freezing into liquid nitrogen. 50-nm cryosections were picked up in a 1:1 2% methyl cellulose and 2.3 M sucrose solution and stored at 4°C. For immunolabeling, ultrathin cryosections were blocked in blocking buffer containing 1% BSA mixed with 0.1% Aurion BSA-C, 0.1% glycine, 0.1% gelatin, and 1% Tween-20 in 0.1 M PHEM. As a primary antibody, rabbit anti-GFP antibody (Ab6556; Abcam) was used at 1:100 dilution in blocking buffer for 1 h and a 12-nm gold-conjugated anti--rabbit IgG antibody (Jackson ImmunoResearch Laboratories) as a secondary antibody at 1:30 dilution for 30 min. Cryosections were fixed with 1% glutaraldehyde, contrasted for 5 min in a drop of uranyl oxalate solution and for 5 min in a drop of uranyl acetate-methyl cellulose pH 4.0 solution on ice ([@bib63]). Ultrathin sections were examined using a Tecnai Spirit transmission electron microscope (FEI Company) at 120 kV accelerating voltage. Micrographs were acquired using a CCD camera (MegaView III; Olympus) and the image acquisition analySIS software (Olympus). In all cases, the specificity of immunolabeling was accessed by comparing the number of immunogold particles in the strains expressing GFP-tagged Pct1, Kes1, or Ldb16 with a isogenic untagged strain.

EM tomography {#s20}
-------------

Cells were cryoimmobilized by high-pressure freezing using a EM HPM100 (Leica). Freeze substitution of frozen samples was performed in an Automatic Freeze substitution System EM AFS-2 (Leica), using acetone containing 0.1% of uranyl acetate and 1% water, for 3 d at −90°C. On the fourth day, the temperature was slowly increased, by 5°C/h, to −45°C. At this temperature, samples were rinsed in acetone and then infiltrated and embedded in Lowicryl HM20 for 3 d. For electron tomography, serial sections were collected on Formvar-coated, palladium-copper slot grids. The grids with 250-nm-thick sections were placed in a high-tilt holder (Model 2020; Fischione Instruments), and the cells were recorded on a Tecnai F30 EM operating at 300 kV using the SerialEM software package ([@bib48]). Images were taken every degree over a ±60° range on an FEI Eagle 4K × 4K CCD camera at a magnification of 20,000× and a binning of 2 (pixel size 1.179 nm). The LDs were recorded as dual-axis tilt series. The tilted images were aligned by using the positions of the fiducial gold particles. The tomograms were generated using the R-weighted back-projection algorithm. For supersized LDs, serial sections were acquired. These were aligned and joined using the eTomo graphical user interphase ([@bib39]; [@bib47]; [@bib50]; [@bib32]). Tomograms were displayed as slices one-voxel thick, modeled, and analyzed with the IMOD software package ([@bib38]).

Protein mass spectrometry {#s21}
-------------------------

Trichloroacetic acid precipitated proteins were resuspended in 6 M urea and 200 mM ammonium bicarbonate before reduction (10 mM dithiothreitol) and alkylation (20 mM iodoacetamide). Samples were diluted to 2 M urea and digested with trypsin (1:10 wt/wt) overnight at 37°C. Tryptic peptide mixtures were desalted using a C18 UltraMicroSpin column using three washes with 0.1% formic acid in water, followed by an elution step with 0.1% formic acid in a 1:1 mix of water and acetonitrile ([@bib54]).

Samples were analyzed in a LTQ-Orbitrap Velos Pro mass spectrometer (Thermo Fisher Scientific) coupled to nano-LC (Proxeon) equipped with a reversed-phase chromatography 12-cm column with an inner diameter of 75 µm, packed with 5-µm C18 particles (Nikkyo Technos). Chromatographic gradients were set from 93% buffer A, 7% buffer B to 65% buffer A, 35% buffer B in 60 min with a flow rate of 300 nl/min (buffer A: 0.1% formic acid in water; buffer B: 0.1% formic acid in acetonitrile). The instrument was operated in DDA mode and full mass spectrometry scans with 1 micro scans at resolution of 60,000 were used over a mass range of m/z 250--2,000 with detection in the Orbitrap. After each survey scan, the top 20 most intense ions with multiple charged ions above a threshold ion count of 5,000 were selected for fragmentation at normalized collision energy of 35%. Fragment ion spectra produced via collision-induced dissociation were acquired in the linear ion trap. All data were acquired with Xcalibur software v2.2.

Acquired data were analyzed using the Proteome Discoverer software suite (v1.3.0.339; Thermo Fisher Scientific), and the Mascot search engine (v2.3; Matrix Science) was used for peptide identification. Data were searched against database containing all yeast proteins according to the Saccharomyces Genome Database plus the most common contaminants ([@bib5]). A precursor ion mass tolerance of 7 ppm at the MS1 level was used, and up to three miscleavages for trypsin were allowed. The fragment ion mass tolerance was set to 0.5 D. Oxidation of methionine and protein acetylation at the N terminus were defined as variable modifications. Carbamidomethylation on cysteines was set as a fix modification. The identified peptides were filtered using a false discovery rate \<5%.

Protein areas were normalized intra- and intersamples by median of the log area. A linear modeling approach implemented in *lmFit* function and the empirical Bayes statistics implemented in *eBayes* and *topTable* functions of the Bioconductor *limma* package ([@bib24]; [@bib57]) were used to perform a differential protein abundance analysis. The normalized protein areas of different yeast mutants were compared with *wt* samples. Protein p-values were calculated with *limma* and were adjusted with Benjamini--Hochberg method ([@bib2]). A value of 0.05 was used as a cutoff.

Lipid analysis {#s22}
--------------

Lipids from whole cells or from isolated LDs were extracted following the single-step modification of [@bib20] described by [@bib1]: one volume of cells or LDs suspension was mixed with three volumes of chloroform/methanol 2:1 vol/vol and vortexed at high speed (with glass beads in case of whole cells) for 3 min followed by further shaking for 1 h. 1 vol of 0.9% NaCl was added, and brief vortexing was applied. Samples were centrifuged at 200 *g*, and the lower (chloroform) phase was recovered. The extracts were dried, dissolved in chloroform/methanol 2:1 vol/vol, and analyzed by TLC on silica gel 60 plates (Merk). Phospholipids were resolved with chloroform/ethyl acetate:acetone/isopropanol/ethanol/methanol/water/acetic acid (30:6:6:6:16:28:6:2 vol/vol). Neutral lipids were resolved with hexane/diethyl ether/acetic acid (80:20:1 vol/vol) to three fifths of the plate, dried, and followed by hexane/chloroform (9:1 vol/vol) to four fifths of the plate. DAG and free sterol were resolved with toluene/ethyl acetate/ethyl ether/ammonia-25% (80:10:10:0.2 vol/vol). Bands were stained in a chamber saturated with iodine vapor, scanned, and quantified by densitometry with Quantity One (Bio-Rad). Known standards were included on all plates for identification.

Steady-state lipid labeling for PA quantification {#s23}
-------------------------------------------------

Cultures in SC were diluted to OD~600~ 0.1 in SC or SC supplemented with 75 µM of inositol and grown for 24 h at 30°C in the presence of 1 µCi/ml \[1-^14^C\]acetate (45--60 mCi/mmol; Perkin Elmer). Lipids were extracted as described in the previous section with of 5 mM HCl, resolved by TLC with chloroform/methanol/acetic acid (65:25:8 vol/vol), scanned on a Typhoon Trio phosphorimager (Amersham Biosciences), and quantified with Quantity One (Bio-Rad).

Online supplemental material {#s24}
----------------------------

Fig. S1 shows purity and lipid composition of LDs isolated from wt, *fld1Δ*, and *ldb16Δ*. Fig. S2 shows the distribution of Scs2, Scs2- and PA-binding domains of Opi1 and PA in *fld1Δ* and *ldb16Δ* mutants. Fig. S3 shows relocalization and levels of amphipathic-helix containing proteins in seipin complex mutants. Fig. S4 shows that LD assembly causes phospholipid-packing defects in seipin complex mutants. Videos 1 and 2 show the 3D reconstruction and segmentation of a 250-nm-thick section of a *wt* cell, respectively. Videos 3 and 4 show the 3D reconstruction and segmentation of serial sections of a *ldb16Δ* cell containing supersized LDs, respectively. Videos 5 and 6 show 3D reconstructions of serial sections of a *ldb16Δ* cell containing aggregated LDs. Video 7 shows the segmentation of a *ldb16Δ* cell in Video 6. Table S1 shows the LD-specific proteins reduced in LDs isolated from *fld1Δ* and *ldb16Δ* cells. Table S2 shows the peripheral membrane proteins increased in LDs isolated from *fld1Δ* and *ldb16Δ* cells. Tables S3 and S4 show the quantification of immuno-EM analysis. Tables S5, S6, and S7 list the yeast strains, plasmids, and primers used in this study, respectively. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201502070/DC1>.
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